Industries

The companies have been looking for ways to gain an edge through deals with the firms that control drug benefits.

The U.S. agreed to exempt U.K. pharmaceutical products from tariffs.

The plan to eventually phase out rebates portends a seismic shift in the flow of billions of dollars among drugmakers, insurers and employers.

A new survey by Equitable finds that tailor-made messaging is more important than ever.

Key to cost containment lies in partnering with transparent PBMs, a more thoughtful approach to prescribing GLP-1s and encouraging the uptake of biosimilars.

While Life Insurance Awareness Month in September offers an opportunity for promotion, a year-round campaign would fill coverage gaps.

Without the right contractual terms in place, hidden costs may mar pooled purchasing power at the expense of employer clients.

The incentives to encourage non-generic brands will encourage pharmacies to keep them in stock and increase their profits, says UnitedHealth's CEO.

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone.

President Biden's Inflation Reduction Act is expected to save taxpayers an estimated $237 billion over the next decade.

Definitive steps can be taken to strategically optimize pharmacy benefits in a way that balances cost with quality care.

CEO of WellTheory Ellen Rudolph shares her journey to diagnosis and why it inspired her to start her company.

Rising costs and ever-changing employee needs mean that employers need to reconsider their health plan model.

Drug shortages have soared to a five-year peak as low profit margins discourage investment in generic manufacturing.

Pairing coverage with the highest quality behavior change support will put employers ahead of the curve